Health Catalyst(US:HCAT)2026-03-12 22:02Financial Data and Key Metrics Changes - For the full year of 2025, the company generated $311.1 million in revenue and $41.4 million of Adjusted EBITDA, with total revenue for Q4 2025 at $74.7 million, down from $79.6 million in the prior year period [25][26] - Adjusted gross margin for Q4 2025 was 53.5%, compared to 46.6% in the prior year period, while for the full year, it was 51.1% driven by technology gross margin of 67.4% and professional services gross margin of 18.3% [27] - Adjusted operating expenses for Q4 2025 were $26.2 million, representing 35% of revenue, down from $29.2 million or 37% of revenue in Q4 2024 [28] Business Line Data and Key Metrics Changes - Technology revenue for Q4 2025 was $51.9 million, while professional services revenue was $22.8 million, with the decline in professional services revenue attributed to reductions in FTE service offerings and exiting unprofitable pilot arrangements [25][26] - For the full year, technology revenue increased 7% year-over-year to $208.3 million, while professional services revenue declined 8% [27] Market Data and Key Metrics Changes - The company finished the year with 32 net new logos, ahead of the target of 30 but below the initial expectation of 40 [25] - The tech plus TAMS dollar-based retention closed the year at 93% [25] Company Strategy and Development Direction - The company is focused on long-term success, emphasizing a back-to-basics approach to deliver measurable outcomes across cost efficiency, clinical improvement, and consumer experience [10][17] - Plans include tightening leadership focus, improving operational rigor, and simplifying the commercial story to better articulate the value proposition [12][16] - The company aims to strengthen and simplify its commercial engine to drive technology ARR bookings and improve retention through predictable migrations [19][21] Management's Comments on Operating Environment and Future Outlook - Management noted that the market is under pressure, with clients needing to manage costs while maintaining clinical quality [56] - The company is currently in an assessment mode to best position itself for shareholder value, with no immediate plans for selling the company [44][46] - The first quarter of 2026 is expected to see revenue of $68 million to $70 million and Adjusted EBITDA of $7 million to $8 million, with anticipated challenges due to migration-related revenue declines [33][35] Other Important Information - The company incurred impairment charges on goodwill and intangible assets of $110.2 million during 2025, primarily due to a decrease in market cap and forecast revisions [31] - The company is reviewing its cost structure to ensure strategic capital allocation and is focused on expanding technology bookings and margins [13][22] Q&A Session Summary Question: Does the strategic review include the possibility of selling the company? - Management is focused on positioning the company for long-term success and creating shareholder value, with no definitive answer on selling the company at this time [44][46] Question: Can you elaborate on the transition impact regarding the $52 million in data platform revenue? - The $52 million encompasses both integrated applications and data platform infrastructure, with the latter experiencing the highest pressure during the migration [50][51] Question: What insights were gained regarding bookings and demand environment in Q4? - The market is in need of better cost management and clinical quality, with significant pressure on profitability for provider clients [56] Question: How does the company plan to maintain client relationships amid data platform disintermediation? - The company aims to retain application relationships while addressing the challenges posed by data platform infrastructure changes [52][66] Question: What is the expected impact of the $12.5 million in ARR churn on 2026? - Approximately 75% of the $12.5 million is expected to impact 2026, with more details to be provided in future guidance [84][85]